ASNS-low ovarian cancer

Metabolic Inhibitor Iacs-6274 Shows Early Antitumor Effects In Underserved Patients With Advanced Cancers

Timothy A. Yap, M.B.B.S, Ph.D.

Drug developed by MD Anderson’s Therapeutics Discovery division is well-tolerated with effective glutaminase inhibition in Phase I trial The glutaminase (GLS1) inhibitor IACS-6274, discovered and developed by The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery division, appears to be well-tolerated […]

Contact The Katy News

Have a news tip, story idea, advertising question, or community announcement?

The Katy News
Serving Katy and the surrounding communities

General Inquiries: info@thekatynews.com
Advertising: ads@thekatynews.com
Article Submissions: articles@thekatynews.com

Phone: 281-396-3333

Follow Us

Copyright © The Katy News

Business Directory Add Listing